Quarterly Result28 Apr 2025, 06:52 pm
Vimta Labs Reports Q4 & FY25 Results: 31.4% YoY Total Income Growth, 19.1% PAT Margin, Ventures into Biologics Contract R&D Services
AI Summary
Vimta Labs Limited, a leading Contract Research and Testing Organisation, has announced its financial results for the quarter and year ended March 31, 2025. The company reported a Total Income of Rs. 961 Mn in Q4 FY25, with EBITDA margins at 36.1% and PAT margin at 19.1%. The company has also ventured into Biologics Contract Research and Development services, focusing on Novel Biologic Entities (NBEs), biosimilars, and peptide-based therapeutics. The new service line is expected to contribute revenues from FY27.
Key Highlights
- Total Income for Q4 FY25 was at Rs. 961 Mn
- EBITDA for Q4 FY25 was Rs. 347 Mn with a margin of 36.1%
- PAT for Q4 FY25 was Rs. 183 Mn with a margin of 19.1%
- Vimta has ventured into Biologics Contract R&D services
- The Board of Directors have recommended a final dividend of Rs.2/- per equity share for the financial year 2024-25